The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis

Rush, Barret; Wiskar, Katie; Berger, Landon; Griesdale, Donald

doi:10.1016/j.rmed.2015.12.005

Cited by 83 publications

(73 citation statements)

References 22 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More recently, two national cohorts were reported. Analysis of the US cohort revealed an in-hospital mortality of approximately 50% (51.6% with IMV and 30.9% in NIV) among 2481 patients with IPF who were mechanically ventilated [50]. Analysis of the Japanese cohort demonstrated that among 209 patients receiving an average of 12.8 days of IMV, short-term (within 30 days) survival was 44.6% and long-term (within 90 days) survival of 24.6%.…”

Section: Improving Prognosismentioning

confidence: 99%

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis

2017

View full text Add to dashboard Cite

Recognising recent advances, the definition and diagnostic criteria for acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) have been updated by an international working group. The new definition describes any acute, clinically significant respiratory deterioration (both idiopathic and triggered events) characterised by evidence of new widespread alveolar abnormality. The new criteria require a previous or concurrent diagnosis of IPF, an acute worsening or development of dyspnoea typically less than 1 month in duration, chest imaging evidence on computed tomography (CT) of new bilateral ground-glass opacity and/or consolidation superimposed on a background imaging pattern of usual interstitial pneumonia not fully explained by cardiac failure or fluid overload. Due to high in-hospital mortality rates, current treatment guidelines say that the majority of patients with AE-IPF should not receive mechanical ventilation. However, new data suggest that the prognosis may have improved. This modest improvement in overall survival seen in more recent studies may be the result of differences in the diagnostic criteria, study design, baseline clinical risk factors and/or improvements in management. Based on our updated knowledge of possible preventive and therapeutic measures, including mechanical ventilation and pharmacological therapies, the current approach to the treatment of AE-IPF requires careful decision-making.

show abstract

Section: Improving Prognosismentioning

confidence: 99%

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis

2017

View full text Add to dashboard Cite

show abstract

“…It may be that more contemporary management approaches to respiratory failure and acute lung injury (e.g. low tidal volume ventilation) are improving in-hospital survival (61); this is an area in need of careful study.…”

Section: Managementmentioning

confidence: 99%

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Collard

et al. 2016

Am J Respir Crit Care Med

1,082

1,116

View full text Add to dashboard Cite

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically significant, respiratory deterioration of unidentifiable cause. The objective of this international working group report on acute exacerbation of idiopathic pulmonary fibrosis was to provide a comprehensive update on the topic. A literature review was conducted to identify all relevant English text publications and abstracts. Evidence-based updates on the epidemiology, etiology, risk factors, prognosis, and management of acute exacerbations of idiopathic pulmonary fibrosis are provided. Finally, to better reflect the current state of knowledge and improve the feasibility of future research into its etiology and treatment, the working group proposes a new conceptual framework for acute respiratory deterioration in idiopathic pulmonary fibrosis and a revised definition and diagnostic criteria for acute exacerbation of idiopathic pulmonary fibrosis.

show abstract

“…Invasive mechanical ventilation has been consistently associated with a very high mortality among IPF patients in the ICU setting (>90%) [87] . However, in a recent, large, nationwide cohort analysis in the USA, in-hospital mortality among patients with IPF requiring invasive mechanical ventilation was approximately 50% [88] . This trend may also be due to contemporary management approaches to acute lung injury (lung-protective ventilation strategies).…”

Section: Mechanical Ventilationmentioning

confidence: 99%

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment

Funke-Chambour

Azzola²,

Adler³

et al. 2017

Respiration

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the choice between available drugs, their use in particular subgroups and clinical situations, time of treatment onset, termination, combination or switch, or nonpharmacologic management. To guide Swiss respiratory physicians in this evolving field still characterized by numerous areas of uncertainty, the Swiss Working Group for interstitial and rare lung diseases of the Swiss Respiratory Society provides a position paper on the diagnosis and treatment of IPF.

show abstract

The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis

Abstract: In a large national cohort, the in-hospital mortality of patients with IPF who are mechanically ventilated is approximately 50%.

Cited by 83 publications

References 22 publications

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment

Contact Info

Product

Resources

About